 |
|
|
| |
Preliminary Safety and Efficacy Results From TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Nancy Reau1, Fred Poordad2, Jeff rey V Enejosa3, Asma Siddique4, Humberto Aguilar5, Jacob Lalezari6, Franco Felizarta7, Peter J Ruane8, Peter Varunok9, David E Bernstein10, Douglas Dieterich11,
Gregory Everson12, Yiran B Hu3, Tami Pilot-Mati as3, Nancy S Shulman3, Sanjeev Arora13
1Rush University Medical Center, Chicago, Illinois, United States; 2The Texas Liver Insti tute/University of Texas Health Science Center, San Antonio, Texas, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Virginia Mason Medical Center, Seatt le, Washington, United States;
5Louisiana Research Center, LLC, Shreveport, Louisiana, United States; 6Quest Clinical Research, San Francisco, California, United States; 7Private practi ce, Bakersfi eld, California, United States; 8Ruane Medical and Liver Health Insti tute, Los Angeles, California, United States;
9Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States; 10North Shore University Hospital, Manhasset, New York, United States; 11Mount Sinai School of Medicine, Icahn School of Medicine, New York, New York, United States;
12University of Colorado, Denver School of Medicine, Aurora, Colorado, United States; 13University of New Mexico, Albuquerque, New Mexico, United States
|
| |
|
|
|
|
|
